The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Very Long-Term Prognosis of Patients with Malignant Uveal Melanoma
Abstract
PURPOSE: To investigate the very long-term prognosis of patients with uveal melanoma and the clinical characteristics influencing it. METHODS: Charts, registry data, and histopathologic specimens of 289 consecutive patients with choroidal and ciliary body melanoma treated in the district of the Helsinki University Central Hospital, Finland, between 1962 and 1981 were audited. Definitions for coding the cause of death were adapted from the Collaborative Ocular Melanoma Study (COMS). Competing risks were taken into account by using cumulative incidence analysis and competing risks regression. RESULTS: Of the 289 patients treated, 239 were deceased at the end of follow-up. The audited cause of death was uveal melanoma in 145 (61%) of them. The median follow-up of the 50 survivors was 28 years. The original histopathologic diagnosis of metastasis and second cancer was correct in 91% of all specimens, but immunohistochemical reassessment changed 10% of biopsy and 7% of autopsy diagnoses. Of 45 positive autopsies, 18% were performed without suspicion of melanoma. Uveal melanoma-related mortality was 31% (95% confidence interval [CI], 26-37) by 5 years, 45% (95% CI, 40-51) by 15 years, 49% (95% CI, 43-55) by 25 years, and 52% (95% CI, 45-58) by 35 years, according to cumulative incidence analysis. Of patients who died of uveal melanoma, 62%, 90%, 98%, and 100% did so within 5, 15, 25, and 35 years, respectively. Between 15 and 35 years, 20% to 33% of deaths were still due to uveal melanoma. By competing risks regression analysis, the hazard ratio was 1.08 (P=0.0012) for each millimeter increase in tumor diameter, 2.27 (P=0.0076) for extraocular growth, and 1.89 (P=0.0011) for ciliary body involvement. CONCLUSIONS: Metastatic uveal melanoma was the leading single cause of death throughout the study. Cumulative incidences provide a sound basis for patient counseling and design of trials.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A Proportional Hazards Model for the Subdistribution of a Competing Risk
Fine, J. P., & Gray, R. J. (1999) · Journal of the American Statistical Association · doi:10.1080/01621459.1999.10474144 · Cited by 14,290
Modeling Survival Data: Extending the Cox Model
Therneau, T. M., & Grambsch, P. M. (2000) · Statistics for Biology and Health · doi:10.1007/978-1-4757-3294-8 · Cited by 8,674
A Class of $K$-Sample Tests for Comparing the Cumulative Incidence of a Competing Risk
Gray, R. J. (1988) · The Annals of Statistics · doi:10.1214/aos/1176350951 · Cited by 4,960
Survival Analysis: A Self-Learning Text
Carpenter, M. (1997) · Technometrics · doi:10.1080/00401706.1997.10485091 · Cited by 1,811
(2001) · Archives of Ophthalmology · doi:10.1001/archopht.119.7.969 · Cited by 771
Survival Analysis: A Practical Approach.
Smith, P. J., Parmar, M. K. B., & David, M. (1996) · Journal of the American Statistical Association · doi:10.2307/2291609 · Cited by 730
Survival Analysis With Long-Term Survivors
(1998) · Technometrics · doi:10.1080/00401706.1998.10485509 · Cited by 443
The Prognostic Value of Tumor Blood Vessel Morphology in Primary Uveal Melanoma
Folberg, R., Rummelt, V., Parys-Van Ginderdeuren, R., Hwang, T., Woolson, R. F., Pe'er, J., & Gruman, L. M. (1993) · Ophthalmology · doi:10.1016/s0161-6420(93)31470-3 · Cited by 421
Eskelin, S. (2000) · Ophthalmology · doi:10.1016/s0161-6420(00)00182-2 · Cited by 403
Collaborative Ocular Melanoma Study Group
Fine, S. L. (1999) · Archives of Family Medicine · doi:10.1001/archfami.8.1.11-a · Cited by 305
Seddon, J. M., Albert, D. M., Lavin, P. T., & Robinson, N. (1983) · Archives of Ophthalmology · doi:10.1001/archopht.1983.01040020896012 · Cited by 301
(1998) · American Journal of Ophthalmology · doi:10.1016/s0002-9394(98)00039-7 · Cited by 260
Handbook of Statistics in Clinical Oncology
Crowley, E. B. J., & Ankerst, D. P. (2001) · Medical Entomology and Zoology · Cited by 257
Survival rates with uveal melanoma in the United States: 1973–1997
Singh, A. D., & Topham, A. (2003) · Ophthalmology · doi:10.1016/s0161-6420(03)00077-0 · Cited by 250
Microvascular Loops and Networks as Prognostic Indicators in Choroidal and Ciliary Body Melanomas
Makitie, T., Summanen, P., Tarkkanen, A., & Kivela, T. (1999) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/91.4.359 · Cited by 162
Self-citationUveal Melanoma: Growth Rate and Prognosis
Char, D. H., Kroll, S., & Phillips, T. L. (1997) · Archives of Ophthalmology · doi:10.1001/archopht.1997.01100160184007 · Cited by 78
Abrahamsson, M. (1983) · Acta Ophthalmologica · doi:10.1111/j.1755-3768.1983.tb04350.x · Cited by 32
Cited by
Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma
Nathan, P., Hassel, J. C., Rutkowski, P., Baurain, J.-F., Butler, M. O., Schlaak, M., Sullivan, R. J., Ochsenreither, S., Dummer, R., Kirkwood, J. M., et al. (2021) · New England Journal of Medicine · doi:10.1056/nejmoa2103485 · Cited by 924
Kivela, T. (2009) · British Journal of Ophthalmology · doi:10.1136/bjo.2008.150292 · Cited by 721
Self-citation(2005) · Archives of Ophthalmology · doi:10.1001/archopht.123.12.1639 · Cited by 621
Metastatic disease from uveal melanoma: treatment options and future prospects
Carvajal, R. D., Schwartz, G. K., Tezel, T., Marr, B., Francis, J. H., & Nathan, P. D. (2017) · British Journal of Ophthalmology · doi:10.1136/bjophthalmol-2016-309034 · Cited by 438
Melanoma epidemiology, biology and prognosis
Ali, Z., Yousaf, N., & Larkin, J. (2013) · European Journal of Cancer Supplements · doi:10.1016/j.ejcsup.2013.07.012 · Cited by 278
Metadata
- Authors
- Kujala, E., Ma¨kitie, T., & Kivela¨, T.
- Venue
- Investigative Opthalmology & Visual Science
- Published
- 2003-11-01
- Volume
- 44
- Issue
- 11
- Pages
- 4651
- ISSN
- 0146-0404 (ISSN-L)
- 1552-5783
- OpenAlex
- W2055835855
- Cited by
- 1,045
- References
- 17
- FWCI
- 13.34
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.